Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Indivior Pharmaceuticals (INDV) EBIAT (2022 - 2026)

Indivior Pharmaceuticals has reported EBIAT over the past 5 years, most recently at $89.0 million for Q1 2026.

  • For Q1 2026, EBIAT rose 89.36% year-over-year to $89.0 million; the TTM value through Mar 2026 reached $251.0 million, up 3685.71%, while the annual FY2025 figure was $210.0 million, 2900.0% up from the prior year.
  • EBIAT for Q1 2026 was $89.0 million at Indivior Pharmaceuticals, down from $102.0 million in the prior quarter.
  • Over five years, EBIAT peaked at $102.0 million in Q4 2025 and troughed at -$183.0 million in Q4 2022.
  • A 5-year average of $13.3 million and a median of $41.5 million in 2022 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: crashed 429.27% in 2023 and later surged 385.71% in 2025.
  • Year by year, EBIAT stood at -$183.0 million in 2022, then surged by 129.51% to $54.0 million in 2023, then plummeted by 61.11% to $21.0 million in 2024, then surged by 385.71% to $102.0 million in 2025, then decreased by 12.75% to $89.0 million in 2026.
  • Business Quant data shows EBIAT for INDV at $89.0 million in Q1 2026, $102.0 million in Q4 2025, and $42.0 million in Q3 2025.